IWCLL Criteria for Treating CLL Other Considerations at Relapse Risk Factors at Relapse IGHV Status Affects Clinical Course Case 1 65YearOld Man Assessing This Patients Options TP53 Mutationdel17p and CIT ID: 634398
Download Presentation The PPT/PDF document "Personalized Therapy in Relapsed or Ref..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Personalized Therapy in Relapsed or Refractory CLLSlide2Slide3Slide4
IWCLL Criteria for Treating CLLSlide5
Other Considerations at RelapseSlide6
Risk Factors at RelapseSlide7
IGHV
Status Affects Clinical CourseSlide8
Case 1: 65-Year-Old ManSlide9
Assessing This Patient's OptionsSlide10
TP53 Mutation/del(17p) and CITSlide11
Monoclonal Antibodies and del(17p)Slide12
Efficacy of Ibrutinib in del(17p)Slide13
Safety of Ibrutinib Slide14
Additional Considerations for Novel AgentsSlide15
Overall Findings From RESONATE Slide16
Efficacy of Venetoclax in del(17p)Slide17
Safety of Venetoclax in Phase 2 TrialSlide18
TLS With VenetoclaxSlide19
PI3K-δ Inhibitor IdelalisibSlide20
Case 2: 43-Year-Old ManSlide21
Considerations for Sequencing TherapySlide22
Investigational Agents for Refractory CLLSlide23
Additional Considerations for Sequencing TherapySlide24
Minimal Residual DiseaseSlide25
Case 3: 77-Year-Old W
omanSlide26
Assessing This Patient's OptionsSlide27
Prolonged LymphocytosisSlide28
Summary of Safety Concerns With Novel AgentsSlide29
Concluding RemarksSlide30
AbbreviationsSlide31
Abbreviations (cont)Slide32
Abbreviations (cont)Slide33
Abbreviations (cont)